title: Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers.
abstract: The optimal approach to obtain an adequate graft for transplantation in patients with poor peripheral blood stem cell (PBSC) mobilization remains unclear. We retrospectively assessed the impact of different strategies of second-line stem cell harvest on the transplantation outcome of patients who failed PBSC mobilization in our institution. Such patients were distributed into three groups: those who proceeded to steady-state bone marrow (BM) collection (group A, n = 34); those who underwent second PBSC mobilization (group B, n = 41); those in whom no further harvesting was carried out (group C, n = 30). PBSC harvest yielded significantly more CD34+ cells than BM collection. Autologous transplantation was performed in 30, 23 and 11 patients from groups A, B and C, respectively. Engraftment data and transplantation outcome did not differ significantly between groups A and C. By contrast, group B patients had a faster neutrophil recovery, required less platelet transfusions and experienced less transplant-related morbidity, as reflected by lower antibiotics needs and shorter hospital stays. In conclusion, remobilization of PBSC constitutes an effective approach to ensure a rapid hematopoietic engraftment and a safe transplantation procedure for poor mobilizers, whereas unprimed BM harvest does not provide any clinical benefit in this setting.
authors.affiliation: Hematology and Medical Oncology Service, Hospital Clínico Universitario, University of Valencia, Valencia, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Goterris
authors.forename: J C
authors.initials: JC
authors.lastname: Hernández-Boluda
authors.forename: A
authors.initials: A
authors.lastname: Teruel
authors.forename: C
authors.initials: C
authors.lastname: Gómez
authors.forename: M J
authors.initials: MJ
authors.lastname: Lis
authors.forename: M J
authors.initials: MJ
authors.lastname: Terol
authors.forename: M
authors.initials: M
authors.lastname: Tormo
authors.forename: C
authors.initials: C
authors.lastname: Solano
authors.forename: C
authors.initials: C
authors.lastname: Arbona
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34; D001773:Blood Cells / Q000166:cytology / Q000187:drug effects; D001854:Bone Marrow Cells / Q000166:cytology / Q000187:drug effects; D016026:Bone Marrow Transplantation / Q000379:methods; D002452:Cell Count; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use; D019337:Hematologic Neoplasms / Q000628:therapy; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods / Q000592:standards; D006801:Humans; D007937:Leukapheresis / Q000379:methods* / Q000592:standards; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D012189:Retrospective Studies; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34; D016179:Granulocyte Colony-Stimulating Factor